Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- FDA approval in ATTR-CM is real but limited to patients with confirmed wild-type or hereditary ATTR-CM.
- The approved indications require confirmation of the diagnosis before treatment is initiated.
- Phenotyping—imaging plus monoclonal exclusion—remains part of the diagnostic evaluation required before treatment.
- Long-term treatment benefit still depends on persistence after approval.
What the FDA Labels Actually Authorize in ATTR-CM
The FDA labels specify the approved patient population rather than use in all forms of infiltrative cardiomyopathy. Both the tafamidis and acoramidis labels indicate treatment of adults with wild-type or hereditary ATTR-CM to reduce cardiovascular mortality and cardiovascular-related hospitalization. Accordingly, an FDA approval is an authorization for patients with confirmed wild-type or hereditary ATTR-CM—the same approach carried by ATTR-CM guidelines and regulation.
Why Approval Assumes a Secure Diagnosis
The approved indications require a secure diagnosis because the approved indication applies only to patients with confirmed disease. That keeps phenotyping central; bone-avid tracer imaging, monoclonal protein exclusion, and the comprehensive diagnostic evaluation for cardiac amyloidosis remain necessary to establish that an infiltrative phenotype is ATTR-CM and not a mimic. The label doesn't perform the diagnosis nor does it replace the diagnostic evaluation required to establish ATTR-CM, so an uncertain diagnosis isn't enough to apply approved therapy confidently.
Why Real-World Value Still Depends on Persistence
Real-world value depends on persistence because regulatory approval alone doesn’t ensure long-term clinical benefit. Long-term clinical benefit is expected to depend on timely treatment initiation, sustained adherence, and appropriate clinical follow-up. Observational adherence experience shows that continuity isn't automatic, which is why regulatory approval and long-term treatment persistence are distinct but complementary components of effective disease management. Both are required to achieve the clinical benefits demonstrated in the pivotal trials.
Clinical Decision Point
Appropriate use of FDA-approved ATTR-CM therapies depends less on the presence of a left ventricular wall thickening than on whether the patient is confirmed to have the approved phenotype and maintain long-term treatment over time. When diagnosis is secure and persistence is realistic, the label supports treatment; when either is missing, the therapy may be used outside the patient population for which it has been approved and studied.
Frequently Asked Questions
What do FDA labels approve in ATTR-CM?
They approve treatment of adults with confirmed wild-type or hereditary ATTR-CM to reduce cardiovascular mortality and cardiovascular-related hospitalization. This is an approved indication, not a general approval for all forms of infiltrative cardiomyopathy.
Why does diagnosis come before the label?
Diagnosis comes first because the label assumes the patient meets the approved indication. Imaging and monoclonal exclusion establish that the diagnosis is confirmed as ATTR-CM before approved therapy is applied.
Does approval guarantee real-world benefit?
No. Benefit still depends on starting early, maintaining therapy, and monitoring clinical response during follow-up; approval authorizes use but does not ensure long-term treatment persistence or clinical benefit.
Part of the Spotlight On ATTR-CM resource center.
References:
- VYNDAQEL and VYNDAMAX (tafamidis) prescribing information. U.S. Food and Drug Administration
- ATTRUBY (acoramidis) prescribing information. U.S. Food and Drug Administration
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. Journal of Managed Care & Specialty Pharmacy
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.